首页> 美国卫生研究院文献>Current Cardiology Reviews >Beyond Adding Years to Life: Health-related Quality-of-life andFunctional Outcomes in Patients with Severe Aortic Valve Stenosis at HighSurgical Risk Undergoing Transcatheter Aortic Valve Replacement
【2h】

Beyond Adding Years to Life: Health-related Quality-of-life andFunctional Outcomes in Patients with Severe Aortic Valve Stenosis at HighSurgical Risk Undergoing Transcatheter Aortic Valve Replacement

机译:超越增加生命的岁月:与健康相关的生活质量和严重高主动脉瓣狭窄患者的功能结局经导管主动脉瓣置换术的手术风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aortic valve stenosis (AVS) is the most frequent acquired valvular heart disease in western industrialized countries and its prevalence considerably increases with age. Once becoming symptomatic severe AVS has a very poor prognosis. Progressive and rapid symptom deterioration leads to an impairment of functional status and compromised healthrelated quality-of-life (HrQoL) simultaneously. Until recently, surgical aortic valve replacement (SAVR) has been the only effective treatment option for improving symptoms and prolonging survival. Transcatheter aortic valve replacement (TAVR) emerged as an alternative treatment modality for those patients with severe symptomatic AVS in whom the risk for SAVR is considered prohibitive or too high. TAVR has gained clinical acceptance with almost startling rapidity and has even quickly become the standard of care for the treatment of appropriately selected individuals with inoperable AVS during recent years. Typically, patients currently referred for and treated by TAVR are elderly with a concomitant variable spectrum of multiple comorbidities, disabilities and limited life expectancy. Beyond mortality and morbidity, the assessment of HrQoL is of paramount importance not only to guide patient-centered clinical decision-making but also to judge this new treatment modality. As per current evidence, TAVR significantly improves HrQoL in high-surgical risk patients with severe AVS with sustained effects up to two years when compared with optimal medical care and demonstrates comparable benefits relative to SAVR.Along with a provision of a detailed overview of the current literature regarding functional and HrQoL outcomes in patients undergoing TAVR, this review article addresses specific considerations of the HrQoL aspect in the elderly patient and finally outlines the implications of HrQoL outcomes for medico-economic deliberations.
机译:主动脉瓣狭窄(AVS)是西方工业化国家中最常见的获得性瓣膜性心脏病,其患病率随着年龄的增长而大大增加。一旦成为有症状的严重AVS,其预后很差。症状的快速进展会同时导致功能状态受损和健康相关的生活质量(HrQoL)下降。直到最近,外科主动脉瓣置换术(SAVR)一直是改善症状和延长生存期的唯一有效治疗选择。经导管主动脉瓣置换术(TAVR)已成为严重症状性AVS患者的替代治疗方式,在这些患者中,SAVR的风险被认为过高或过高。 TAVR几乎以惊人的速度获得了临床认可,并且近年来已迅速成为治疗适当选择的AVS无法手术的个体的治疗标准。通常,目前由TAVR转诊和治疗的患者是老年患者,伴有多种合并症,残疾和预期寿命有限的变化。除死亡率和发病率外,对HrQoL的评估不仅对指导以患者为中心的临床决策,而且对于判断这种新的治疗方式都至关重要。根据目前的证据,TAVR可以显着改善患有严重AVS的高手术风险患者的HrQoL,与最佳医疗护理相比,可持续长达两年的疗效,并且与SAVR相比具有可比的益处。关于接受TAVR的患者的功能和HrQoL结局的文献,这篇综述文章讨论了老年患者中HrQoL方面的具体考虑,并最终概述了HrQoL结局对药物经济研究的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号